BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 22, 2016
View Archived Issues
Ionis, AstraZeneca move antisense drug for cardiovascular disease into preclinical studies
Read More
Medix seeks Mexican clearance to begin phase III study of tesofensine for obesity
Read More
Galapagos reports topline results from phase II study of potentiator GLPG-1837 in cystic fibrosis
Read More
NIH awards grant to Albert Einstein College of Medicine
Read More
MaxCyte and Washington University form immuno-oncology collaboration
Read More
Phase I data for novel anti-CD22 CAR therapy in pediatric and young adult patients with ALL
Read More
DiaMedica reports positive results from phase I study of KLK1 product
Read More
PvP Biologics advancing treatment for celiac disease
Read More
Novartis to acquire Encore Vision
Read More
PsiOxus Therapeutics and BMS sign exclusive worldwide license agreement for NG-348
Read More
Preliminary phase I data for Viralym-C in patients with refractory CMV infection
Read More
Positive topline data presented from phase IIb BRID study of biphasic remogliflozin
Read More
Genetic modeling and therapeutic targeting of ETV6-NTRK3 fusion in ALL
Read More
HMGA1 polymorphism protects against proliferative diabetic retinopathy
Read More
Marketing authorization for Zebinix extended
Read More
Neos Therapeutics resubmits NDA for Cotempla XR-ODT
Read More
I-MAB granted rights to Ferring's olamkicept
Read More
Merrimack announces discontinuation of phase II HERMIONE trial of MM-302
Read More
Astellas' acquisition of Ganymed Pharmaceuticals now complete
Read More
NanoCarrier discontinues phase I trial of NC-6004 for head and neck cancer
Read More
FDA issues complete response letter regarding Lutathera
Read More
Actelion in exclusive negotiations with Johnson & Johnson
Read More
Inovio Pharmaceuticals reports positive results from first human study of Zika vaccine
Read More
Phase III study of emicizumab prophylaxis in hemophilia A meets primary endpoint
Read More
Merck & Co. and SD R&D patent PDE2 inhibitors
Read More
Merck & Co. discloses BTK inhibitors
Read More
Orion describes alpha2C-adrenoceptor antagonists
Read More
Chinese scientists develop CDK/cyclin inhibitors
Read More
Antiviral drug ribavirin shows promise as new therapeutic option for glioblastoma
Read More